Get started
Author

Alfredo Vozza

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
2022 · Sara Volpe, Giuseppe Lisco, et al. · Nutrients · 66
PDF
Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
2024 · Sara Volpe, Alfredo Vozza, et al. · Nutrients · 20
Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
2023 · Paolo Basile, Andrea Igoren Guaricci, et al. · Journal of Clinical Medicine · 15
PDF
Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study
2025 · Alfredo Vozza, Domenico Triggiani, et al. · Frontiers in Endocrinology · 11
PDF
Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience
2022 · Giuseppina Piazzolla, Alfredo Vozza, et al. · Open Medicine · 10
PDF
Glucagon‐Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26‐Week Prospective Observational Real‐Life Study
2025 · Alfredo Vozza, Sara Volpe, et al. · Journal of Diabetes Research · 6
PDF
Clinical phenotyping in sarcoidosis management.
2021 · Giuseppe Domenico Rana, Miriana d'Alessandro, et al. · Sarcoidosis vasculitis and diffuse lung diseases · 6
PDF
Real-Life Characteristics of Patients with COPD and Discordant CAT-mMRC Questionnaires
2025 · Andrea Portacci, Vitaliano Quaranta, et al. · Journal of Clinical Medicine · 1
PDF
The Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes Mellitus: A Brief Report
2023 · Alfredo Vozza, Erasmo Porfido, et al. · Endocrine Metabolic & Immune Disorders - Drug Targets · 1
Can Sleep Hypoxic Measures Predict Long-Term Adherence to Positive Airway Pressure Treatments?
2026 · Andrea Portacci, Sara Quaranta, et al. · Clocks & Sleep
Inhibition of the renin–angiotensin system does not improve the outcomes of hepatocellular carcinoma treated with atezolizumab–bevacizumab
2026 · Tommaso Zurli, Alfredo Vozza, et al. · Digestive and Liver Disease
PDF
Exploratory Identification of Multidimensional COPD Clusters Using Unsupervised Analysis
2026 · Andrea Portacci, Mariafrancesca Grimaldi, et al. · Medicina
GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma
2026 · Alfredo Vozza, Filippo Biagi, et al. · Internal and Emergency Medicine
PDF
Impact of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) on outcomes in hepatocellular carcinoma treated with atezolizumab–bevacizumab.
2026 · Costanza Winchler, Fabio Marra, et al. · Journal of Clinical Oncology
FRI-381 Inhibition of the renin–angiotensin system does not improve the outcomes of hepatocellular carcinoma treated with atezolizumab–bevacizumab
2026 · Alfredo Vozza, Costanza Winchler, et al. · Journal of Hepatology
Navigating TIPS in the era of ageing and metabolic comorbidity: a contemporary narrative review of risk, resilience, and outcomes
2026 · Davide Roccarina, Dario Saltini, et al. · Gastroenterology report
Early Prediction of In-Hospital Mortality in Patients with Acute Infections: Development of the Acute Severity Infection Score (ASIs)
2025 · Alessio Comitangelo, Alfredo Vozza, et al. · Infectious Diseases and Therapy
PDF
Works count: 17
Citation count: 136
H-index: 6
I10-index: 5
Year
Topic
Type